RIATOMSK.RU
0°C
25 апреля 2024  |  
8:46
  |  
0°C
9:05 PM  December 4, 2017

TSU chemists get the first domestic technology of pentamine synthesis

© предоставлено пресс-службой ТГУTSU chemists get the first domestic technology of pentamine synthesis

TOMSK, Dec 4 – RIA Tomsk. Scientists of Tomsk State University (TSU) developed the first domestic technology for the synthesis of pentamine – a substance used for the production of pharmaceuticals; the technology will allow to start the production of this substance in Russia, which is being procured abroad, the press service of the university said on Monday.

According to the press service, now the Russian enterprises acquire a pentamine from China, which is the main exporter of the substance in the world.

"Pentamine is used for the production of injections, which are used at hypertensive crisis, pulmonary edema and brain, etc. In the world market a kilogram of pentamine costs about 4 thousand dollars, but its prime cost is lower. Raw materials have a democratic price, therefore, the production of a substance is economically advantageous", – the head of the TSU Laboratory for Organic Synthesis Victor Mal'kov is quoted in the message.

© РИА Томск. Павел Стефанский
It is specified that the technology created by the chemists of TSU will allow to establish domestic production of a substance which, not yielding to a foreign analogue, will have a lower price. The research of Tomsk pentamine showed that it has a good quality and degree of purification, which means that the substance is suitable for the production of medicines.

"As the initial components for the synthesis, only one substance of imported production was used, all the remaining components – are Russian, some of which are produced in Siberia. There are a number of enterprises in Russia capable of mastering the production of this substance", – Mal'kov said.

It is planned that the first trial batch will be received at TSU. After that the Engineering Chemical and Technological Center (ECTC) of the university will deal with bringing new technology to the market. Its implementation seems to be beneficial both for industrialists interested in cost-effective production, and for patients who will be able to purchase the drug at lower price.

Наверх
Сайт РИА Томск /riatomsk.ru/ содержит информацию, подготовленную Региональным информационным агентством "Томск" (РИА Томск) с территорией распространения – Российская Федерация, зарубежные страны.
РИА Томск зарегистрировано в Федеральной службе по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор) 06 ноября 2019 г. Свидетельство о регистрации ИА № ФС 77-77122.
Настоящий ресурс может содержать материалы 18+. Материалы, размещенные на правах рекламы, выходят под знаком "#" и/или "реклама". РИА Томск не несет ответственности за партнерские материалы.
Рейтинг@Mail.ru
Яндекс.Метрика
ЧИТАЙТЕ
РИА в VK
Главные новости дня в нашей рассылке